secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001193125-24-248760
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma completes $30M+stock acquisition of ImmPACT Bio, gains CD19/20 CAR T candidate
--------------------------------------------------------------------------------

- Upfront: $30M cash (adjusted for ~$12M ImmPACT cash) plus 37.5M Lyell shares; contingent milestone shares up to 12.5M and low-single-digit royalty.
- IMPT-314 (dual-targeting CD19/20 CAR T) expected to start pivotal trial in 2025 for third-line CAR-naïve B-cell non-Hodgkin lymphoma.
- Sumant Ramachandra, former ImmPACT CEO, appointed to Lyell's Board of Directors.
- Lyell expects cash to fund operations into 2027 through clinical milestones including pivotal trial initiation for IMPT-314.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/0001193125-24-248760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/d901554d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-248760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer